BHVN Biohaven Ltd.
Pharmaceutical Preparations · NYSE · SEC CIK 1935979 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY30.4%
TTM EPS YoY49.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-161.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets137.3%
Debt / equity—
Current ratio3.05x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-20.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $635.07M | $795.87M |
| SG&A expense | $110.31M | $89.24M |
| Operating income | -$745.38M | -$885.11M |
| Pretax income | -$737.38M | -$845.69M |
| Income tax | $1.44M | $735,000 |
| Net income | -$738.82M | -$846.42M |
| EBITDA | -$735.46M | -$877.26M |
| EPS (basic) | -6.86 | -9.28 |
| EPS (diluted) | -6.86 | -9.28 |
| Weighted avg. shares (diluted) | 107.62M | 91.23M |
| Balance sheet | ||
| Cash & equivalents | $229.96M | $102.54M |
| Short-term investments | $89.18M | $386.86M |
| Current assets | $368.33M | $538.47M |
| PP&E, net | $15.96M | $17.32M |
| Goodwill | $1.39M | $1.39M |
| Intangibles | $18.40M | $18.40M |
| Total assets | $451.45M | $615.11M |
| Current liabilities | $115.93M | $154.23M |
| Total liabilities | $399.38M | $191.67M |
| Shareholders' equity | $52.07M | $423.44M |
| Shares outstanding | 132.78M | 101.22M |
| Cash flow statement | ||
| Operating cash flow | -$609.44M | -$582.45M |
| Capital expenditure | $715,000 | $4.05M |
| Free cash flow | -$610.15M | -$586.50M |
| Investing cash flow | $300.56M | -$244.97M |
| Financing cash flow | $439.12M | $677.77M |
| Depreciation & amortization | $9.92M | $7.86M |
| Stock-based compensation | $112.36M | $71.96M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.